Vaccination is currently the most effective means of controlling influenza and preventing its complications and mortality in persons at risk.

Once a year, a meeting of WHO experts takes place, leading to a recommendation on the influenza A and B strains that should be used for the production of vaccine for the coming influenza season.

This study is designed to test the safety/reactogenicity and the immunogenicity of the Fluviral Trivalent Split Virion Influenza Vaccine containing the influenza strains recommended for the 2007-2008 season.

Inclusion Criteria:

• Healthy male and female adults, 18 years of age and older.
• Female subject of non-childbearing potential. Written informed consent obtained from subject.

Exclusion Criteria:

• Acute disease at the time of enrollment.
• Blood pressure abnormalities.
• Any immunosuppressive condition, such as HIV or cancer.
• Renal impairment, hepatic dysfunction, complicated insulin-dependent diabetes mellitus.
• Unstable cardiopulmonary disease requiring chronic medical therapy or associated with functional impairment.
• Any demyelinating disease, including Guillain-Barré syndrome.
• Alcohol consumption and/or drug abuse.
• Receipt of an influenza vaccine within 9 months prior to enrollment or of any vaccines within 30 days prior to enrollment.
• Any known or suspected allergy to the Fluviral vaccine.

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.